← Back

Jilin Jian Yisheng Pharmaceutical Co Ltd

Jilin Jian Yisheng Pharmaceutical Co., Ltd. is a China-based company that, with its subsidiaries, researches, develops, produces, wholesales, retails, imports, and exports pharmaceutical products. Its offerings include capsules, injections, tablets, granules, cosmetics, ginseng products, bee products, and food items such as acai collagen solid drinks, multivitamin mineral tablets, collagen peptide juice drinks, and fruit lemon powder. The company also engages in contract manufacturing, health food and special medical products, fertilizers and beverages, Chinese medicinal herb extracts, cosmetics wholesale and retail, road freight, bio-organic and microbial fertilizer R&D, leasing, packaging printing, paper cutting and sales, human stem cell technology, and traditional spice products. It additionally provides life beauty services, Chinese medicine health and wellness services, and technical development, consulting, exchange, promotion, and transfer services. Founded in 1997, it is headquartered in Ji'an, China.

Country
Price · split & dividend adjusted
News & notes moving 002566.CS
002566.CS2

Yisheng Pharmaceutical Releases 2026 Interim Report with Net Profit of 26.8311 Million Yuan

Yisheng Pharmaceutical released its 2026 interim report. The company's total operating revenue was 338 million yuan, net profit attributable to the parent company was 26.8311 million yuan, and net cash inflow from operating activities was 40.0734 million yuan. The company's latest asset-liability ratio was 22.16 percent, up 0.18 percentage points from the previous quarter. Gross margin was 75.18 percent, return on equity was 1.20 percent, and diluted earnings per share was 0.08 yuan. The company's latest total asset turnover was 0.11 times, inventory turnover was 0.05 times, and the number of shareholders was 19,300. The top ten shareholders held 160 million shares, accounting for 48.32 percent of total share capital.
002566.CS
Jiemian·25dRead more →
002566.CS▼5

Yisheng Pharmaceutical Suspends Production and Sales of Some Products; Affected Products Account for Low Revenue Share

Yisheng Pharmaceutical announced that it has received a risk control measures notice from the Jilin Provincial Medical Products Administration. Due to one serious defect found during a targeted inspection by the National Medical Products Administration inspection center for the product Bujin Tablets, posing a safety hazard, the company has decided to implement risk control measures of suspending production and sales for the production lines related to Shengmai Injection and Bujin Tablets. The affected products, Shengmai Injection and Bujin Tablets, accounted for 7.65 percent and 0.01 percent of the company's total revenue in 2025, respectively. The company stated that the risk control measures will lead to a temporary halt in production capacity, short-term supply tightness for some drugs, and product recalls will incur logistics and disposal costs, potentially causing loss of some market orders and disruption of terminal supply, further impacting current profits. However, this has not yet resulted in the invalidation of core operating qualifications or drug approvals, and will not directly trigger a delisting risk warning. The company has proactively initiated a level-three recall for the relevant batch of Bujin Tablets, with a total of 9,562 bottles produced and 2,400 bottles sold.
002566.CS ▼
证券时报·76dRead more →
© 2026 MarketDXAsset